Tekmira Pharmaceuticals is a biopharmaceutical company and a leader in developing RNA interference (RNAi) therapeutics. The company is focused on advancing novel RNAi therapeutics and supplying pharmaceutical partners with its leading lipid nanoparticle delivery technology. Based in Vancouver, B.C., Tekmira has worked in the nucleic acid delivery field for more than a decade and has vast intellectual property covering LNPs. For more information, visit the company’s Web site at www.tekmirapharm.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: